Generic:

Daclatasvir

Therapeutic Class:

Hepatitis C Antivirals

Composition:

MyDekla 60mg = Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 60mg daclatasvir

Description:

MyDekla use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults

• Hepatitis C genotype 1
• Recurrent HCV infection post-liver transplant
• Hepatitis C genotype 3

Dosage:

Genotype 1:

• Without cirrhosis: MyDekla plus MyHep for 12 weeks
• Compensated (Child-Pugh A) cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
• Decompensated (Child-Pugh B or C) cirrhosis: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
• Posttransplant: MyDekla plus sofosbuvir MyHep (sofosbuvir) plus ribavirin for 12 weeks

Genotype 3:

• Without cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
• Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis: MyDekla plusMyHep (sofosbuvir) plus ribavirin for 12 weeks
• Post transplant: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks

Presentation:

MyDekla 60 mg tab is available in pack of 28 tablets